Study of a gene therapy for wet age-related macular degeneration
Part of Eyes & vision clinical trials.
This trial tests a one-time gene therapy injection for wet AMD that may reduce the need for regular eye injections. It is for people who have already responded to anti-VEGF injections but want a longer-lasting treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had cataract surgery at least 12 weeks before the first study visit.
- You have wet AMD in one eye with an active abnormal blood vessel area smaller than 10 disc areas.
- You have received at least 2 anti-VEGF injections in that eye in the last 6 months and your doctor says you responded well.
- Your wet AMD was first diagnosed less than 4 years ago.
- You do not have a large pocket of fluid or bleeding under the retina in the center of your vision.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
This study tests a new gene therapy injection called SKG0106 for people with wet AMD. The treatment is given as an injection into the eye and aims to reduce the need for frequent anti-VEGF shots.
This study tests a new medicine called SKG0106, given as an injection into the eye, for people with wet age-related macular degeneration (AMD). It aims to see if it is safe and effective in treating the leaky blood vessels that cause vision loss.
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
This trial tests a gene therapy injection into the eye to treat diabetic retinopathy (eye damage from diabetes) before it progresses. The goal is to slow or prevent vision loss and potentially delay the need for laser treatment or other injections.
This trial tests a one-time gene therapy injection (IXO-vec) for people with wet age-related macular degeneration (nAMD). It aims to reduce the need for frequent eye injections by helping the eye make its own medicine to block the growth of harmful blood vessels.
Hear when a new Neovascular Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.